NewAmsterdam Pharma Co N.V. (NAMS) · Sep 29, 2026 · Other events

NewAmsterdam Pharma starts Alzheimer’s trial, but proof remains years away

Phase 2b initiated — First participant dosed; approximately 400 participants planned

NewAmsterdam Pharma’s Alzheimer’s trial is now dosing patients, adding a new development path for obicetrapib without providing efficacy evidence yet.

NewAmsterdam is moving from a late-stage cardiovascular development story toward a broader cardiometabolic and neurodegenerative platform; its European obicetrapib commercialization effort has also advanced, while several cardiovascular Phase 3 programs remain active.

The Alzheimer’s program has officially moved into clinical testing. The first participant has been dosed in SPINOZA, a randomized Phase 2b study testing obicetrapib in people with biomarker evidence of preclinical Alzheimer’s disease but no noticeable symptoms.

Filing metricSPINOZA design
Planned enrollmentApproximately 400 participants (About the Phase 2b SPINOZA Trial)
Treatment period52 weeks double-blind (About the Phase 2b SPINOZA Trial)
DoseObicetrapib 10 mg or placebo, randomized 1:1 (About the Phase 2b SPINOZA Trial)
Primary endpointChange in plasma p-tau217 at Week 52 (About the Phase 2b SPINOZA Trial)
Optional extensionAt least 26 weeks open-label (About the Phase 2b SPINOZA Trial)

This is a development milestone, not an efficacy readout. The trial will measure whether obicetrapib changes Alzheimer’s-related blood biomarkers, led by p-tau217, alongside cognitive measures; no SPINOZA safety or efficacy results are available yet. 〔0〕

The scientific rationale is promising but still indirect. NewAmsterdam is carrying forward a prespecified BROADWAY biomarker analysis in which p-tau217 changes were statistically lower versus placebo, including among ApoE4 carriers, but that analysis came from a cardiovascular trial subset that was not controlled for baseline differences and did not include a safety analysis in the Alzheimer’s population. 〔1〕

The surprise is limited because trial initiation was already part of the 2026 plan. What is new is execution—the first patient is dosed and the genotype-stratified design is underway—not a change in strategy or proof that obicetrapib affects Alzheimer’s disease. The company still has to show that a biomarker effect translates into meaningful disease modification.

Bottom line: SPINOZA broadens obicetrapib’s opportunity and confirms NewAmsterdam is executing on a previously signaled Alzheimer’s expansion. It matters strategically, but it does not yet change the evidence base for the drug in neurodegenerative disease.

What to watch next

SPINOZA primary p-tau217 readout after 52 weeks

Original filing on SEC EDGAR

More NewAmsterdam Pharma Co N.V. news

NewAmsterdam Pharma starts Alzheimer’s trial, but proof remains years away | NAMS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.